433 related articles for article (PubMed ID: 29872077)
1. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice.
Perera AP; Fernando R; Shinde T; Gundamaraju R; Southam B; Sohal SS; Robertson AAB; Schroder K; Kunde D; Eri R
Sci Rep; 2018 Jun; 8(1):8618. PubMed ID: 29872077
[TBL] [Abstract][Full Text] [Related]
2. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
3. Celastrol augments sensitivity of NLRP3 to CP-456773 by modulating HSP-90 and inducing autophagy in dextran sodium sulphate-induced colitis in rats.
Saber S; Abd El-Kader EM; Sharaf H; El-Shamy R; El-Saeed B; Mostafa A; Ezzat D; Shata A
Toxicol Appl Pharmacol; 2020 Aug; 400():115075. PubMed ID: 32470352
[TBL] [Abstract][Full Text] [Related]
4. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
6. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke.
Ismael S; Zhao L; Nasoohi S; Ishrat T
Sci Rep; 2018 Apr; 8(1):5971. PubMed ID: 29654318
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
9. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
Zhang W; Ba G; Tang R; Li M; Lin H
Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
[TBL] [Abstract][Full Text] [Related]
10. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
11. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
12. Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90/NLRP3 interaction and inducing autophagy in rats.
Saber S; El-Kader EMA
Inflammopharmacology; 2021 Feb; 29(1):237-251. PubMed ID: 32594364
[TBL] [Abstract][Full Text] [Related]
13. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
14. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
[TBL] [Abstract][Full Text] [Related]
15. MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury.
Ismael S; Nasoohi S; Ishrat T
J Neurotrauma; 2018 Jun; 35(11):1294-1303. PubMed ID: 29295651
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion.
Wang H; Chen H; Jin J; Liu Q; Zhong D; Li G
Life Sci; 2020 Jun; 251():117638. PubMed ID: 32251636
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
Coll RC; Robertson AA; Chae JJ; Higgins SC; Muñoz-Planillo R; Inserra MC; Vetter I; Dungan LS; Monks BG; Stutz A; Croker DE; Butler MS; Haneklaus M; Sutton CE; Núñez G; Latz E; Kastner DL; Mills KH; Masters SL; Schroder K; Cooper MA; O'Neill LA
Nat Med; 2015 Mar; 21(3):248-55. PubMed ID: 25686105
[TBL] [Abstract][Full Text] [Related]
18. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
[TBL] [Abstract][Full Text] [Related]
19. NLRP3 Inflammasome Regulates Development of Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes in Mice With Acute Pancreatitis.
Sendler M; van den Brandt C; Glaubitz J; Wilden A; Golchert J; Weiss FU; Homuth G; De Freitas Chama LL; Mishra N; Mahajan UM; Bossaller L; Völker U; Bröker BM; Mayerle J; Lerch MM
Gastroenterology; 2020 Jan; 158(1):253-269.e14. PubMed ID: 31593700
[TBL] [Abstract][Full Text] [Related]
20. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
